J&J dives deep­er in­to bis­pecifics; Spring­Works an­nounces re­search deal over Stan­ford pro­fes­sor's work

Mass­a­chu­setts biotech F-Star en­tered a li­cens­ing and col­lab­o­ra­tion agree­ment with J&J in a deal po­ten­tial­ly worth $1.35 bil­lion in mile­stones.

In ex­change for $17.5 mil­lion up­front, F-Star an­nounced this morn­ing that the biotech is giv­ing J&J world­wide, ex­clu­sive and roy­al­ty-bear­ing li­cense to do R&D and com­mer­cial­ize up to five new bis­pe­cif­ic an­ti­bod­ies for J&J ther­a­peu­tic tar­gets us­ing F-star’s re­search plat­forms. J&J will take on all re­spon­si­bil­i­ties for R&D and com­mer­cial­iza­tion un­der the agree­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER